Patents by Inventor Kazumasa Nara
Kazumasa Nara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8911855Abstract: The present invention relates to a masking tape base material using a machine-made Japanese paper as a base paper. The machine-made Japanese paper comprises a mercerized softwood pulp and a kraft pulp. The weight percent of the mercerized softwood pulp in a mixture of the mercerized softwood pulp and the kraft pulp is from 10 to 70% by weight. The machine-made Japanese paper is impregnated with a resin having a glass transition temperature of not higher than ?25° C. in an amount of 20% by weight or more. One surface of the impregnated machine-made Japanese paper is further coated with a resin having a glass transition temperature (Tg) of from 0 to 40° C. in a dry coating amount of from 2 to 20 g/m2.Type: GrantFiled: January 16, 2012Date of Patent: December 16, 2014Assignee: KJ Specialty Paper Co., Ltd.Inventors: Noriaki Kawashima, Kazumasa Nara
-
Publication number: 20130260116Abstract: The present invention relates to an impregnation-coating type Japanese paper masking tape base material obtained by coating a resin having a glass transition temperature (Tg) of from 0 to 40° C. in a dry coating amount of from 2 to 20 g/m2 on one surface of a paper in which a machine-made Japanese paper having a basis weight of from 25 to 40 g/m2, in which a fiber component thereof includes a mercerized softwood pulp and a kraft pulp, and a blending ratio of the mercerized softwood pulp is from 10 to 70% by weight, is impregnated with a resin having a glass transition temperature of not higher than ?25° C. in an amount of 20% by weight or more.Type: ApplicationFiled: January 16, 2012Publication date: October 3, 2013Applicant: KJ SPECIALTY PAPER CO., LTD.Inventors: Noriaki Kawashima, Kazumasa Nara
-
Patent number: 8530654Abstract: Crystals, amorphous substances, salts, and hydrates of a salt of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid having PDE4 inhibitory action are provided. These compounds are useful for treating allergic diseases such as atopic dermatitis.Type: GrantFiled: February 15, 2008Date of Patent: September 10, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Eiichi Yamamoto, Osamu Asano, Jun Niijima, Kazumasa Nara
-
Patent number: 8399520Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.Type: GrantFiled: March 15, 2011Date of Patent: March 19, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe
-
Publication number: 20120004315Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: March 15, 2011Publication date: January 5, 2012Inventors: Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe
-
Patent number: 7960412Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; ??(I-1) formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.Type: GrantFiled: August 20, 2009Date of Patent: June 14, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe
-
Patent number: 7834049Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.Type: GrantFiled: April 4, 2005Date of Patent: November 16, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Publication number: 20100267754Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.Type: ApplicationFiled: June 10, 2010Publication date: October 21, 2010Inventors: Toshiaki WAKABAYASHI, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Patent number: 7790885Abstract: A process for preparing a compound represented by the formula (I): comprising reacting a compound represented by the formula (II) or salt thereof: with a compound represented by the formula (III): in the presence of a condensation reagent, wherein R1 represents 1) optionally substituted azetidin-1-yl, 2) optionally substituted pyrrolidin-1-yl, 3) optionally substituted piperidin-1-yl, etc.; R2, R3, R4 and R5 may be the same or different and each represents hydrogen or fluorine; and R6 represents hydrogen or fluorine.Type: GrantFiled: August 27, 2007Date of Patent: September 7, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Mitsuo Nagai, Tomohiro Matsushima, Atsushi Kamada, Kazunori Wakasugi, Shuji Shirotori, Shinya Abe, Kazumasa Nara, Takahisa Sakaguchi
-
Publication number: 20100217001Abstract: Disclosed is a commercially advantageous method for producing a pyrazole fused ring derivative (such as a 7-phenylpyrazolo[1,5-a]pyridine derivative).Type: ApplicationFiled: October 17, 2008Publication date: August 26, 2010Inventors: Keizo Sato, Kazumasa Nara, Naoyuki Shimomura
-
Publication number: 20090325930Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; ??(I-1) formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: August 20, 2009Publication date: December 31, 2009Inventors: Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe
-
Patent number: 7612114Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.Type: GrantFiled: June 22, 2005Date of Patent: November 3, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe
-
Publication number: 20090163715Abstract: A compound represented by the general formula below or a salt thereof is a useful intermediate in the production of a [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine compound that has excellent cell adhesion inhibitory effect and cell invasion inhibitory effect and therefore is useful as a therapeutic or prophylactic agent for various inflammatory diseases and autoimmune diseases induced by the adhesion and invasion of leukocytes, such as inflammatory bowel diseases (particularly ulcerative colitis or Crohn's disease), irritable bowel syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, asthma and atopic dermatitis. wherein R1 and R2 independently represent hydrogen or a protecting group for an amino group, or R1 and R2 bond together to form an optionally substituted pyrrole ring.Type: ApplicationFiled: May 25, 2006Publication date: June 25, 2009Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Mitsuo Nagai, Kazumasa Nara, Kazunori Wakasugi, Toshihiko Naito
-
Publication number: 20090062539Abstract: Crystals, amorphous substances, salts, and hydrates of salt of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid have PDE4 inhibitory action and are useful for treating allergic diseases such as atopic dermatitis.Type: ApplicationFiled: February 15, 2008Publication date: March 5, 2009Applicant: Eisai R&D Management Co., Ltd.Inventors: Eiichi YAMAMOTO, Osamu Asano, Jun Niijima, Kazumasa Nara, Kazuki Miyazaki
-
Publication number: 20080214815Abstract: A process for preparing a compound represented by the formula (I): comprising reacting a compound represented by the formula (II) or salt thereof: with a compound represented by the formula (III): in the presence of a condensation reagent, wherein R1 represents 1) optionally substituted azetidin-1-yl, 2) optionally substituted pyrrolidin-1-yl, 3) optionally substituted piperidin-1-yl, etc.; R2, R3, R4 and R5 may be the same or different and each represents hydrogen or fluorine; and R6 represents hydrogen or fluorine.Type: ApplicationFiled: August 27, 2007Publication date: September 4, 2008Applicant: Eisai R&D Management Co., Ltd.Inventors: Mitsuo Nagai, Tomohiro Matsushima, Atsushi Kamada, Kazunori Wakasugi, Shuji Shirotori, Shinya Abe, Kazumasa Nara, Takahisa Sakaguchi
-
Publication number: 20060116364Abstract: The present invention provides a compound represented by the following formula [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereofType: ApplicationFiled: June 22, 2005Publication date: June 1, 2006Applicant: Eisai Co., Ltd.Inventors: Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe
-
Publication number: 20050176712Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.Type: ApplicationFiled: April 4, 2005Publication date: August 11, 2005Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Patent number: 6787534Abstract: The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.Type: GrantFiled: June 10, 2002Date of Patent: September 7, 2004Assignee: Eisai Co., Ltd.Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Naoko Tsukahara, Takashi Owa
-
Publication number: 20040018192Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.Type: ApplicationFiled: July 18, 2002Publication date: January 29, 2004Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Patent number: 6673787Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.Type: GrantFiled: March 18, 2002Date of Patent: January 6, 2004Assignee: Eisai Co., Ltd.Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara